Funded Startups in Kingston
Five funded entries are shown for Kingston, spanning from 2021-11-18 (BAKX Therapeutics) through 2025-11-24 (MindImmune Therapeutics).
Five funded entries are shown for Kingston, spanning from 2021-11-18 (BAKX Therapeutics) through 2025-11-24 (MindImmune Therapeutics). Among disclosed amounts, the $25M Series A for BAKX Therapeutics (2021-11-18) is the clear outlier: it dwarfs the next-largest disclosed round of $10M (MindImmune Therapeutics, 2025-11-24), while the remaining disclosed amount shown is far smaller at $180K (Edenesque, 2024-04-23).
Sector and stage classifications are concentrated but uneven. Three of the five companies are in healthcare-adjacent categories (MindImmune Therapeutics in Pharmaceuticals/Biotechnology/Healthcare; BAKX Therapeutics in Health Care; Edenesque in Food and Beverage), and four of the five entries are either “Series Unknown” or “undisclosed” (Cyclic Materials on 2025-04-01 is undisclosed; SmartTerm on 2023-05-24 is undisclosed; Edenesque on 2024-04-23 and SmartTerm are “Series Unknown”). Geographically, the Kingston label splits across multiple jurisdictions (United States, Ontario, Pennsylvania, Saint Andrew, and New York), suggesting the list reflects several Kingston locales rather than one single metro.
Most recent rounds
5 shownRelated listings
Frequently asked
Which disclosed round is the largest in this Kingston set, and how does it compare to other disclosed amounts?
BAKX Therapeutics’ $25M Series A on 2021-11-18 is the largest disclosed amount, and it dwarfs the next-largest disclosed round of $10M by MindImmune Therapeutics on 2025-11-24; Edenesque’s $180K on 2024-04-23 sits far below both.
Do these entries cluster in time, or are they evenly spread across years?
The dates span 2021-11-18 through 2025-11-24, without a tight multi-month cluster: the list includes 2025-11-24 (MindImmune), 2025-04-01 (Cyclic Materials), 2024-04-23 (Edenesque), 2023-05-24 (SmartTerm), and 2021-11-18 (BAKX Therapeutics).
Are Kingston-linked locations concentrated in a single country/province, or split across multiple jurisdictions?
The Kingston name is split across several places: United States (MindImmune Therapeutics in Kingston, United States; Edenesque in Kingston, Pennsylvania), Ontario, Canada (Cyclic Materials in Kingston, Ontario), Saint Andrew, Jamaica (SmartTerm in Kingston, Saint Andrew), and New York, United States (BAKX Therapeutics in Kingston, New York).
How dominant is “Series Unknown” or “undisclosed” in this list?
Four of the five entries lack a concrete disclosed series: Cyclic Materials (2025-04-01) is “undisclosed,” SmartTerm (2023-05-24) is “undisclosed,” and both Edenesque (2024-04-23) and SmartTerm (also shown as “Series Unknown” classification) are not assigned a standard series label.
Are there notable sector patterns or outliers among the industries shown?
Healthcare-adjacent categories appear repeatedly (MindImmune Therapeutics in Pharmaceuticals/Biotechnology/Healthcare; BAKX Therapeutics in Health Care), while Edenesque is in Food and Beverage and Cyclic Materials is Manufacturing, making the list more mixed on sector than the “healthcare” cluster would suggest.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.